Yusuke Nakamura to Proportional Hazards Models
This is a "connection" page, showing publications Yusuke Nakamura has written about Proportional Hazards Models.
Connection Strength
0.274
-
Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. Jpn J Clin Oncol. 2011 Aug; 41(8):1023-30.
Score: 0.084
-
Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project. J Epidemiol. 2017 Mar; 27(3S):S29-S35.
Score: 0.031
-
Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activity. Cancer Sci. 2016 Mar; 107(3):298-306.
Score: 0.029
-
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
Score: 0.025
-
Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep. 2012 11; 6(5):937-43.
Score: 0.023
-
Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer Sci. 2012 Mar; 103(3):577-86.
Score: 0.022
-
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011 Jul; 102(7):1298-305.
Score: 0.021
-
Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics. 2010 Sep; 20(9):565-8.
Score: 0.020
-
Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes Chromosomes Cancer. 2010 Apr; 49(4):353-67.
Score: 0.019